< News, Press, & Events

Press Release

GenomeNext Embeds Mastermind Genomic Search Results in Olympus Platform for Scientific Literature Curation

GenomeNext Embeds Mastermind Genomic Search Results in Olympus Platform for Scientific Literature Curation

GenomeNext and Genomenon Partner to Speed Variant Curation for Whole Exome and Whole Genome Analysis

ANN ARBOR, Michigan – February 20, 2018 - GenomeNext, LLC announced today that it has embedded Genomenon’s Mastermind search results in its Olympus Platform to simplify and accelerate variant curation for genomic analysis. Efficacious variant interpretation is a critical but challenging requirement to translate genomics into clinical care and medical discovery. Variant curation remains a very labor-intensive bottleneck often requiring inefficient, manual processes that can result in missed information and delays in diagnosis. Integrating Mastermind with GenomeNext’s Olympus Platform dramatically improves and accelerates variant curation, further streamlining automation of genomic analysis and interpretation. The scientific references for each variant, identified across full-text publications and abstracts, and a direct link to the search results in Mastermind, are integrated and seamlessly automated within the Olympus genomic analysis platform.

Genomenon’s Mastermind Genomic Search Engine is the world’s first search engine that connects patient’s genomic data with the evidence from the scientific literature, a key requirement in analyzing a patient’s DNA in precision medicine for cancer and genetic diseases. Genomenon has indexed the medical literature for the scientific evidence that ties genomic data to specific diseases and presents them in a clinical context within Mastermind to accelerate patient diagnosis.

GenomeNext has integrated the Mastermind search results directly into the Olympus Platform, complementing the existing market-leading bioinformatic analysis pipelines, to accelerate and automate variant curation required for clinical genomic interpretation. For each DNA variant discovered, Olympus seamlessly annotates how many literature references were found by the Mastermind search engine and provides a direct link to access the search results for more detailed literature review. Further, the results can be filtered based upon disease, gene and clinical significance, including diagnostic, prognostic and therapeutic information.

“We looked for the best tools to accelerate literature curation and found there is no comparable solution in the market like Mastermind,” said James Hirmas, CEO of GenomeNext. “We’re excited to introduce Olympus as the first automated, end-to-end, genomic analysis platform that includes a comprehensive genomic search engine for associated medical literature, dramatically reducing the time and costs of variant curation, annotation and interpretation.”

GenomeNext and Genomenon also announced a reseller agreement where GenomeNext will sell Mastermind Professional Edition to its Olympus users as part of the Olympus suite.

“We’re thrilled to partner with GenomeNext to offer Mastermind search results inside their Olympus Platform” said Mike Klein, CEO of Genomenon. “Literature curation has been the biggest bottleneck in the clinical NGS pipeline. GenomeNext is tackling that bottleneck by integrating literature curation directly in the Olympus Platform. Combining Mastermind’s proprietary technology with the differentiating bioinformatics and data management capabilities offered by GenomeNext’s Olympus platform, delivers a powerful suite of capabilities to accelerate the implementation of genomic medicine.


Genomenon is a genomics intelligence company dedicated to improving the quality of life of genetic disease and cancer patients by making genomic information actionable. Blending the power of AI with the precision of genomic expertise, the company empowers pharmaceutical companies and the clinical diagnostic community with empirical genomic evidence and insights that both support the development of novel therapeutics and speed diagnostic assessments and treatment recommendations.


GenomeNext is a genomic informatics company dedicated to accelerating the promise and capability of predictive medicine and scientific discovery. We commercialize genomic analysis tools and integrated systems for the evaluation of genetic variation and function. Our advanced informatics and data management solutions are designed to simplify, expedite and enhance genetic analysis workflows. Our solutions provide the market with genomic data and analysis at an unprecedented combination of performance, quality, cost and scale without requiring the investment in high performance computing resources and specialized personnel. For more information, visit www.genomenext.com

Read the Article
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.